A targeted proteomics assay for the preoperative diagnosis of thyroid nodules - PubMed
12 hours ago
- #targeted proteomics
- #thyroid nodules
- #preoperative diagnosis
- A targeted proteomics assay named ThyroProt was developed for preoperative diagnosis of thyroid nodules.
- ThyroProt integrates a 3-protein signature, BRAF V600E mutation status, age, and gender for diagnosis.
- The classifier was validated on 837 FNA samples and tested on 322 samples, achieving an AUC of 0.94 and 90.7% accuracy.
- For Bethesda III/IV nodules, ThyroProt showed 88.0% accuracy, 82.4% sensitivity, and 100% specificity.
- Performance was confirmed in two independent multicenter cohorts with AUCs of 0.87-0.91 and accuracies of 84.3%-85.7%.
- The study highlights the clinical utility of mass-spectrometry-based targeted proteomics for indeterminate thyroid nodules.